MBRX Moleculin Biotech Inc
Company Analysis
Latest News
Moleculin's Leukemia Drug Shows Promise Without Heart Damage — But Can a $14 Million Company Afford to Cross the Finish Line?
Shares of Moleculin Biotech jumped 7.7% to $0.77 on September 14, bucking a broader market selloff, after investors digested encouraging interim data from the...
🟢 Moleculin Biotech is trading 8% up today on higher remission rates without cardiotoxicity
Moleculin Biotech is trading at $0.77, up +7.97%, after encouraging interim Phase 3 Annamycin data highlighted higher remission rates in relapsed or refractory...
🟢 Moleculin Biotech is trading 6% up in pre-market after encouraging interim Phase 3 Annamycin data
Moleculin Biotech is trading 6% up at $0.76 after investors reacted to encouraging interim Phase 3 Annamycin data presented through the H.C. Wainwright...
Moleculin Biotech Reports Higher Phase 3 AML Remissions With No Cardiotoxicity
Moleculin Biotech released its H.C. Wainwright 28th Annual Global Investment Conference presentation on September 11, 2026. The update features interim Phase 3...
🔴 Moleculin Biotech is trading 11.13% down today with no material new catalyst reported
Moleculin Biotech is trading 11.13% down at $0.74, with no material new catalyst reported. - The decline reverses the September 10, 2026 close of $0.83 and...
🔴 Moleculin Biotech is trading 7.21% down today with no clear company-specific catalyst
Moleculin Biotech is trading at $0.77, down 7.21%, with no clear company-specific catalyst explaining the decline. - Reversed the September 10, 2026 close of...
🟢 Moleculin Biotech is trading 5.4% up today as broader markets rally following August inflation data
Moleculin Biotech is trading 5.4% up at $0.87 as broader markets rally following August inflation data. - No clear company-specific catalyst directly explains...
🟢 Moleculin Biotech is trading 5.23% up today with no clear catalyst identified
Moleculin Biotech is trading 5.23% up at $0.81, with no clear company-specific catalyst identified for September 10, 2026. - The latest listed company release...
🟢 Moleculin Biotech is trading 5.84% up in pre-market with no clear company-specific catalyst identified
Moleculin Biotech is trading 5.84% up at $0.81 after no clear company-specific catalyst was identified for September 10, 2026. - The company’s latest listed...
🟢 Moleculin Biotech is trading 6.6% up today with no clear company-specific catalyst identified
Moleculin Biotech is trading at $0.80 (+6.60%), with no clear company-specific catalyst identified for September 9, 2026. - The latest listed company...
🟢 Moleculin Biotech is trading 6.65% up in pre-market with no clear company-specific catalyst identified
Moleculin Biotech is trading 6.65% up at $0.80 after no clear company-specific catalyst was identified for September 09, 2026. - The official release page...
🟢 Moleculin Biotech is trading 12.26% up today
Moleculin Biotech is trading 12.26% up now at $0.80, based on the provided live price context; no clear company-specific catalyst has been identified for...
🟢 Moleculin Biotech is trading 8.5% up; no clear catalyst identified
Moleculin Biotech is trading 8.5% up at $0.77, with no clear company-specific catalyst identified for September 8, 2026. - Recent coverage focuses on earlier...
🟢 Moleculin Biotech is trading 6.57% up today with no confirmed company-specific catalyst identified
Moleculin Biotech is trading 6.57% higher at $0.72, with no confirmed company-specific catalyst identified for September 4, 2026. - Updates focus on the...
🟢 Moleculin Biotech is trading 7.92% up in pre-market — no confirmed catalyst identified
Moleculin Biotech is trading 7.92% up at $0.73 in pre-market with no confirmed company-specific catalyst identified for September 4, 2026. - Recent updates...
🔴 Moleculin Biotech is trading 6.21% down today with no confirmed catalyst identified
Moleculin Biotech is trading at $0.65, down 6.21%, with no confirmed company-specific catalyst identified. - No new company-specific announcement dated...
🟢 Moleculin Biotech is trading 7.38% up today as XBI gains 2.75%
Moleculin Biotech is trading 7.38% up at $0.70, supported primarily by biotech-sector strength, with XBI up 2.75% during regular trading. - No new...
Moleculin Biotech Target Slashed 86% to $3, Buy Rating Maintained
HC Wainwright & Co. reiterated its Buy rating for Moleculin Biotech. The firm lowered its price target from $22.00 to $3.00. This adjustment represents an...
🟢 Moleculin Biotech is trading 6.03% up in after-hours trading with no clear catalyst identified
Moleculin Biotech is trading 6.03% up at $0.69 after an after-hours rebound with no clear company-specific catalyst. - It closed August 28, 2026, at $0.65...
🔴 Moleculin Biotech falls 5.2% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...